Abstract：Objective To explore the effect and safety of Rosuvastatin in the treatment of hyperlipidemia. Methods Forty-six patients with hyperlipidemia admitted to our hospital from December 2016 to December 2017 were selected as the study subjects, they were divided into group A (n=23) and group B (n=23) according to random number table method. Group A was given symptomatic treatment + Simvastatin, group B was given symptomatic treatment + Rosuvastatin, the total effective rate, total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) levels and adverse reactions before and after treatment were compared between the two groups. Results The total effective rate of group B (95.65%) was significantly higher than that of group A(65.22%), the difference was significant (P＜0.05). The levels of TC, TG and LDL-C in the two groups after treatment were lower than those before treatment, the levels of HDL-C were higher than those before treatment, the levels of TC,TG and LDL-C in group B were lower than those in group A, the levels of HDL-C were higher than those in group A,the differences were statistically significant (P＜0.05). The total incidence of adverse reactions in group B (13.04%) was significantly lower than that in group A (47.83%), the difference was statistically significant (P＜0.05). Conclusion Rosuvastatin has a good therapeutic effect on hyperlipidemia patients, can significantly improve the blood lipid metabolism, reduce cholesterol and low density lipoprotein cholesterol levels, drug safety is high.
杨竞；赖晓华；廖尚. 瑞舒伐他汀治疗高脂血症的效果和安全性[J]. 中国当代医药, 2019, 26(9): 130-132.
YANG Jing ；LAI Xiao-hua ；LIAO Shang. Effect and safety of Rosuvastatin in the treatment of hyperlipidemia. 中国当代医药, 2019, 26(9): 130-132.
京公网安备 11010502046607号